Meeting
2022 ASCO Annual Meeting
Genomic landscape and peripheral blood biomarkers of advanced triple-negative breast cancer treated with immune checkpoint blockade: An exploratory analysis of the TQB2450-Ib-07 trial.
Authors
Yiqun Han
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Yiqun Han , Jiayu Wang , Tao Sun , Quchang Ouyang , Jianwen Li , Binghe Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03855358
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1080)
DOI
10.1200/JCO.2022.40.16_suppl.1080
Abstract #
1080
Poster Bd #
458
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
First Author: Meera Patel
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod
Poster
2022 ASCO Annual Meeting
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Biagio Ricciuti
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).
First Author: Natalie Ngoi